Trial Profile
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Early breast cancer
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2009 Planned number of patients changed from 80 to 100, as reported by ClinicalTrials.gov.
- 31 Oct 2007 New trial record.